Medical News

RSS

Orexigen's Empatic Phase 2b results demonstrate weight loss

Orexigen Therapeutics, Inc. today announced that its 24-week, Phase 2b trial for Empatic(TM) (bupropion SR/zonisamide SR), the Company's second late stage investigational combination drug for the treatment of obesity, met its primary efficacy endpoint by demonstrating statistically significantly greater weight loss for both Empatic doses compared to monotherapies and placebo.

1 Oct 2009

Epigentek Group releases SuperSense Methylated DNA Quantification kit

Epigentek Group Inc. today announced that it released the SuperSense(TM) Methylated DNA Quantification Kit to complete its line of methylated DNA quantification products. The SuperSense(TM) kit fluorometrically measures global DNA methylation shifts.

1 Oct 2009

HRA Pharma launches its new generation emergency contraceptive in Europe

HRA Pharma (http://www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate, 30mg), its new generation emergency contraceptive, has been launched in France, Germany and the United Kingdom via local HRA teams. HRA Pharma will progressively launch ellaOne in all European countries over the coming months.

1 Oct 2009

GSK allowed access to DiscoveRx' PathHunter ß-Arrestin parental cell lines and reagents

DiscoveRx Corp. announced today the signing of a global agreement with GSK, a leading pharmaceutical company, to provide access to its PathHunter™ ß-Arrestin parental cell lines, clones and associated reagents for use in GSK’s internal GPCR Screening and Profiling efforts.

1 Oct 2009

Catalyst Pharmaceutical Partners to continue development of CPP-109 drug

Catalyst Pharmaceutical Partners, Inc. today announced that the Company will continue to develop CPP-109 (Catalyst's version of vigabatrin) for the treatment of cocaine and methamphetamine addiction.

1 Oct 2009

VeriChip to commence Phase II development of an in vivo glucose-sensing RFID microchip

VeriChip Corporation and its development partner RECEPTORS LLC, a technology company whose AFFINITY by DESIGN chemistry platform can be applied to the development of selective binding products, announced today that VeriChip plans to fund its existing development partnership with RECEPTORS to launch Phase II development of an in vivo glucose-sensing RFID microchip.

1 Oct 2009

Advaxis announces Phase I trial results of its ADXS11-001 therapeutic cancer vaccine

The Phase I trial of ADXS11-001, the lead vaccine candidate of Advaxis, Inc. (OTCBB: ADXS), the company that pioneered the live, attenuated Listeria monocytogenes (Lm) vaccine, has shown thirty-six (36) month survival in three (3) of the thirteen (13) evaluable patients treated with Advaxis’ therapeutic cancer vaccine, indicating the possibility of persistent immune protection.

1 Oct 2009

Clinical study results of prostate cancer patients treated with CyberKnife Radiosurgery released

Accuray Incorporated, a global leader in the field of radiosurgery, announced today publication of results from a study of early stage prostate cancer patients treated with CyberKnife Radiosurgery.

1 Oct 2009

New website launched provides details on breast cancer risks faced by younger women

A website launched to coincide with National Breast Cancer Awareness Month, at www.earlyactawareness.org, provides a powerful focal point for efforts to pass the EARLY Act.

1 Oct 2009

First prescription foam formulation of benzoyl peroxide available

Onset Therapeutics, a specialty pharmaceutical company focused on dermatology, announced today the commercial availability of BenzEFoam (benzoyl peroxide) 5.3% Emollient Foam, the first prescription foam formulation of benzoyl peroxide.

1 Oct 2009

Health Canada approves VIBATIV for treating complicated skin and skin structure infections

Astellas Pharma Canada, Inc. announced today that Health Canada has approved VIBATIV(TM) (telavancin) for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains.

1 Oct 2009

Phase 2 study of PH20 with regular human insulin confirms faster insulin absorption

Halozyme Therapeutics, Inc. today announced additional Phase 2 results that demonstrated faster insulin absorption and increased peak insulin concentrations in type 1 diabetic patients after co-administration of its recombinant hyaluronidase enzyme (rHuPH20 or PH20) with Humulin® R (regular human insulin), a mealtime insulin.

1 Oct 2009

NCI selects Integral Molecular to map epitopes for monoclonal antibodies

Integral Molecular, Inc. has been selected by the National Cancer Institute (NCI) to map epitopes for monoclonal antibodies directed against cancer biomarkers. Protein targets of interest to the Clinical Cancer Proteomics community will be analyzed using Shotgun Mutagenesis Mapping technology to identify amino acids that are essential for antibody binding, allowing the discovery and characterization of cancer-specific biomarkers.

1 Oct 2009

Talyst collaborates with healthcare consultancy to provide implementation services

Talyst, a leader in pharmacy automation systems, announced today a partnership with RXinnovate, a healthcare consultancy, to offer top-of-the-line implementation services to Talyst's clients in the acute care industry.

1 Oct 2009

Cross Atlantic Commodities and Mercatis Media sign Online Advertising Agreement

Cross Atlantic Commodities, Inc. (Pink Sheets:CXAC), a successful manufacturer of specialty health and beauty products, announced signing an Online Advertising Agreement with Mercatis Media, LLC, Los Angles California.

1 Oct 2009

Women create nationwide movement to eradicate breast cancer

More than 300,000 women from across the U.S. have signed up for the Love/Avon Army of Women creating a nationwide movement to eradicate breast cancer. Eighty percent of the women who have joined the Army of Women have never had breast cancer, but want to play a role in ending the disease once and for all.

1 Oct 2009

CVRx commences enrollment in study evaluating the Rheos System to treat heart failure

CVRx, Inc. reported the first enrollment of a patient in the HOPE4HF Trial, a study that is evaluating the Rheos System to treat heart failure. The Rheos System uses Baroreflex Activation Therapy® technology, an entirely new non-pharmaceutical approach designed to treat cardiovascular disease. The HOPE4HF Trial is being conducted under an approved investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA).

1 Oct 2009

Addrenex submits a sNDA to the FDA for Clonicel

Sciele Pharma, Inc., a Shionogi company, and Addrenex Pharmaceuticals today announced that Addrenex has submitted a supplemental New Drug Application (sNDA) to the United States Food and Drug Administration (FDA) for Clonicel (modified-release clonidine) to treat attention deficit hyperactivity disorder (ADHD).

1 Oct 2009

Resorbable Orthopedics becomes wholly owned subsidiary of Wound Management Technologies

Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM) a rapidly growing provider of specialty medical products, announced today it has closed on its acquisition of Resorbable Orthopedics LLC, a private company with patented technologies including a resorbable bone wax and a delivery system for orthopedic bone void fillers, among others.

1 Oct 2009

The HealthWell Foundation 's panel discussion draws attention on growing crisis of the underinsured

On Tuesday, September 22, 2009, The HealthWell Foundation, one of America's largest co-payment assistance organizations, hosted a panel discussion to help draw attention to the growing crisis of the underinsured and the related challenges of reducing financial barriers to care.

1 Oct 2009

Medical News

Orexigen's Empatic Phase 2b results demonstrate weight loss

Epigentek Group releases SuperSense Methylated DNA Quantification kit

HRA Pharma launches its new generation emergency contraceptive in Europe

GSK allowed access to DiscoveRx' PathHunter ß-Arrestin parental cell lines and reagents

Catalyst Pharmaceutical Partners to continue development of CPP-109 drug

VeriChip to commence Phase II development of an in vivo glucose-sensing RFID microchip

Advaxis announces Phase I trial results of its ADXS11-001 therapeutic cancer vaccine

Clinical study results of prostate cancer patients treated with CyberKnife Radiosurgery released

New website launched provides details on breast cancer risks faced by younger women

First prescription foam formulation of benzoyl peroxide available

Health Canada approves VIBATIV for treating complicated skin and skin structure infections

Phase 2 study of PH20 with regular human insulin confirms faster insulin absorption

NCI selects Integral Molecular to map epitopes for monoclonal antibodies

Talyst collaborates with healthcare consultancy to provide implementation services

Cross Atlantic Commodities and Mercatis Media sign Online Advertising Agreement

Women create nationwide movement to eradicate breast cancer

CVRx commences enrollment in study evaluating the Rheos System to treat heart failure

Addrenex submits a sNDA to the FDA for Clonicel

Resorbable Orthopedics becomes wholly owned subsidiary of Wound Management Technologies

The HealthWell Foundation 's panel discussion draws attention on growing crisis of the underinsured

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Latest News